UBS Group Cuts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $113.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price lowered by analysts at UBS Group from $117.00 to $113.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has a “neutral” rating on the specialty pharmaceutical company’s stock. UBS Group’s price target suggests a potential upside of 9.15% from the company’s current price.

Several other brokerages also recently commented on JAZZ. HC Wainwright reaffirmed a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, May 3rd. Barclays reduced their target price on Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Friday, May 3rd. Piper Sandler upped their target price on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a report on Wednesday, March 20th. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 27th. Finally, Needham & Company LLC reduced their target price on Jazz Pharmaceuticals from $222.00 to $210.00 and set a “buy” rating for the company in a report on Thursday, June 20th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $188.62.

Jazz Pharmaceuticals Trading Down 1.5 %

Shares of Jazz Pharmaceuticals stock opened at $103.53 on Tuesday. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The firm has a market cap of $6.53 billion, a price-to-earnings ratio of 21.35, a price-to-earnings-growth ratio of 1.64 and a beta of 0.58. The business has a fifty day simple moving average of $108.70 and a 200-day simple moving average of $116.35. Jazz Pharmaceuticals has a fifty-two week low of $102.86 and a fifty-two week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing the consensus estimate of $3.53 by ($1.55). The firm had revenue of $901.98 million during the quarter, compared to analyst estimates of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. On average, equities analysts forecast that Jazz Pharmaceuticals will post 15.35 EPS for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 5,000 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the transaction, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at $4,016,369.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Jazz Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock worth $776,551,000 after purchasing an additional 84,941 shares during the last quarter. LSV Asset Management increased its position in Jazz Pharmaceuticals by 1.6% in the 1st quarter. LSV Asset Management now owns 2,380,858 shares of the specialty pharmaceutical company’s stock worth $286,703,000 after purchasing an additional 37,631 shares during the last quarter. Polaris Capital Management LLC increased its position in Jazz Pharmaceuticals by 13.0% in the 1st quarter. Polaris Capital Management LLC now owns 1,432,660 shares of the specialty pharmaceutical company’s stock worth $172,521,000 after purchasing an additional 165,200 shares during the last quarter. Capital World Investors acquired a new position in Jazz Pharmaceuticals in the 1st quarter worth about $171,943,000. Finally, Ameriprise Financial Inc. boosted its stake in shares of Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,299,612 shares of the specialty pharmaceutical company’s stock worth $168,222,000 after acquiring an additional 57,717 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.